Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Chief Financial Officer | August 15, 2018 | August 17, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protagonist Therapeutics, Inc
Report date August 15, 2018 · Filed August 17, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,560 |
Reported balance
After 2018-08-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-08-15 · Grant · Acquired 21,100 · Balance 30,560 F1: Represents grant of the restricted stock units payable solely in common stock that vest as follows: 1/3rd of the total number of shares shall vest on each of February 5, 2019, August 5, 2019 and February 5, 2020. F2: Includes 602 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2018. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.58 · Expires 2028-08-14 | Direct | 14,050 |
Reported balance
After 2018-08-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-08-15 · Grant · Acquired 14,050 · Balance 14,050 F3: 1/3rd of the total number of shares underlying this option shall vest on each of February 5, 2019, August 5, 2019 and February 5, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of the restricted stock units payable solely in common stock that vest as follows: 1/3rd of the total number of shares shall vest on each of February 5, 2019, August 5, 2019 and February 5, 2020.
F2: Includes 602 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2018.
F3: 1/3rd of the total number of shares underlying this option shall vest on each of February 5, 2019, August 5, 2019 and February 5, 2020.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Satsuma Pharmaceuticals, Inc.
Report date June 06, 2023 · Filed June 08, 2023
Section 16 reporting ended · disclosed 2023-06-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-06 transaction · row 1
1 source rowRow 1 · 2023-06-06 · Other · Disposed 13,877 · Balance 0 F1: Disposed of to SNBL23 Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated April 16, 2023, by and between the Issuer, Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation ("Parent"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock at a purchase price of $0.91 per share and one non-transferable contractual contingent value right (the "Offer Price"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.00 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-08 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than $0.91 and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F2: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.60 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-08 · Disposition to issuer · Disposed 80,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than $0.91 and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F2: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.46 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-08 · Disposition to issuer · Disposed 190,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than $0.91 and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F2: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.56 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-06-08 · Disposition to issuer · Disposed 72,340 · Balance 0 F3: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than $0.91 and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F2: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-08 · Disposition to issuer · Disposed 76,595 · Balance 0 F3: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than $0.91 and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F2: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of to SNBL23 Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated April 16, 2023, by and between the Issuer, Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation ("Parent"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock at a purchase price of $0.91 per share and one non-transferable contractual contingent value right (the "Offer Price").
F2: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.
F3: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than $0.91 and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2023 Filed Jun 8, 2023 16:48 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 76,595 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0000899243-23-014901 · doc4.xml · derivative · entry 6 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,595 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than $0.91 and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:48 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 72,340 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0000899243-23-014901 · doc4.xml · derivative · entry 5 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,340 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than $0.91 and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:48 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 190,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0000899243-23-014901 · doc4.xml · derivative · entry 4 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 190,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than $0.91 and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:48 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0000899243-23-014901 · doc4.xml · derivative · entry 3 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than $0.91 and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:48 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $29.00 | $0.00 |
DisclosureSEC source: 0000899243-23-014901 · doc4.xml · derivative · entry 2 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than $0.91 and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 16:48 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | OtherCommon Stock, $0.0001 par value | 13,877 | $0.91 | $12,628.07 |
DisclosureSEC source: 0000899243-23-014901 · doc4.xml · nonDerivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of to SNBL23 Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated April 16, 2023, by and between the Issuer, Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation ("Parent"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock at a purchase price of $0.91 per share and one non-transferable contractual contingent value right (the "Offer Price"). Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 17:40 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001567619-22-012481 · doc1.xml · derivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2032-06-02 F1 · derivative.exercise_date: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from June 3, 2022 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 18:02 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001567619-20-020718 · doc1.xml · derivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-12-03 F1 · derivative.exercise_date: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from December 3, 2020 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:05 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001567619-20-016411 · doc1.xml · derivative · entry 3 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,590 Underlying: Common Stock · 750 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: The option vest and become exercisable in successive, equal monthly installments over four years measured from May 15, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:05 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | SaleCommon Stock, $0.0001 par value | 750 | $22.19 | $16,644.53 |
DisclosureSEC source: 0001567619-20-016411 · doc1.xml · nonDerivative · entry 2 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $21.90 to $22.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:05 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionCommon Stock, $0.0001 par value | 750 | $4.56 | $3,420.00 |
DisclosureSEC source: 0001567619-20-016411 · doc1.xml · nonDerivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 18:40 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001567619-20-014527 · doc1.xml · derivative · entry 3 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,340 Underlying: Common Stock · 1,000 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: The option vest and become exercisable in successive, equal monthly installments over four years measured from May 15, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 18:40 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | SaleCommon Stock, $0.0001 par value | 1,000 | $25.00 | $25,000.00 |
DisclosureSEC source: 0001567619-20-014527 · doc1.xml · nonDerivative · entry 2 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 18:40 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionCommon Stock, $0.0001 par value | 1,000 | $4.56 | $4,560.00 |
DisclosureSEC source: 0001567619-20-014527 · doc1.xml · nonDerivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:15 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001567619-20-012820 · doc1.xml · derivative · entry 7 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,340 Underlying: Common Stock · 1,000 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: The option vest and become exercisable in successive, equal monthly installments over four years measured from May 15, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:15 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | SaleCommon Stock, $0.0001 par value | 306 | $27.59 | $8,443.64 |
DisclosureSEC source: 0001567619-20-012820 · doc1.xml · nonDerivative · entry 6 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $27.50 to $27.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:15 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionCommon Stock, $0.0001 par value | 306 | $4.56 | $1,395.36 |
DisclosureSEC source: 0001567619-20-012820 · doc1.xml · nonDerivative · entry 5 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:15 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | SaleCommon Stock, $0.0001 par value | 394 | $26.70 | $10,520.08 |
DisclosureSEC source: 0001567619-20-012820 · doc1.xml · nonDerivative · entry 4 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $26.40 to $27.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:15 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionCommon Stock, $0.0001 par value | 394 | $4.56 | $1,796.64 |
DisclosureSEC source: 0001567619-20-012820 · doc1.xml · nonDerivative · entry 3 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:15 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | SaleCommon Stock, $0.0001 par value | 300 | $25.63 | $7,690.20 |
DisclosureSEC source: 0001567619-20-012820 · doc1.xml · nonDerivative · entry 2 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $25.35 to $26.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:15 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionCommon Stock, $0.0001 par value | 300 | $4.56 | $1,368.00 |
DisclosureSEC source: 0001567619-20-012820 · doc1.xml · nonDerivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 16:53 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,115 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001567619-20-012533 · doc1.xml · derivative · entry 3 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,480 Underlying: Common Stock · 2,115 shares Expires 2029-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from January 14, 2019 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 16:53 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | SaleCommon Stock, $0.0001 par value | 2,115 | $35.23 | $74,511.87 |
DisclosureSEC source: 0001567619-20-012533 · doc1.xml · nonDerivative · entry 2 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $35.00 to $35.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 16:53 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionCommon Stock, $0.0001 par value | 2,115 | $1.04 | $2,199.60 |
DisclosureSEC source: 0001567619-20-012533 · doc1.xml · nonDerivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 19:31 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001567619-20-011564 · doc1.xml · derivative · entry 3 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,340 Underlying: Common Stock · 1,000 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: The option vest and become exercisable in successive, equal monthly installments over four years measured from May 15, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 19:31 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | SaleCommon Stock, $0.0001 par value | 1,000 | $25.32 | $25,323.50 |
DisclosureSEC source: 0001567619-20-011564 · doc1.xml · nonDerivative · entry 2 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $25.00 to $25.69, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 19:31 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionCommon Stock, $0.0001 par value | 1,000 | $4.56 | $4,560.00 |
DisclosureSEC source: 0001567619-20-011564 · doc1.xml · nonDerivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 20, 2020 Filed May 21, 2020 17:34 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001567619-20-010950 · doc1.xml · derivative · entry 3 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,340 Underlying: Common Stock · 2,000 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: The option vest and become exercisable in successive, equal monthly installments over four years measured from May 15, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| May 20, 2020 Filed May 21, 2020 17:34 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | SaleCommon Stock, $0.0001 par value | 2,000 | $25.00 | $50,000.00 |
DisclosureSEC source: 0001567619-20-010950 · doc1.xml · nonDerivative · entry 2 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 20, 2020 Filed May 21, 2020 17:34 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionCommon Stock, $0.0001 par value | 2,000 | $4.56 | $9,120.00 |
DisclosureSEC source: 0001567619-20-010950 · doc1.xml · nonDerivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 17:31 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001567619-20-006202 · doc1.xml · derivative · entry 3 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,340 Underlying: Common Stock · 1,000 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: The option vest and become exercisable in successive, equal monthly installments over four years measured from May 15, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 17:31 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | SaleCommon Stock, $0.0001 par value | 1,000 | $27.68 | $27,678.00 |
DisclosureSEC source: 0001567619-20-006202 · doc1.xml · nonDerivative · entry 2 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $26.95 to $29.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 17:31 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Exercise / conversionCommon Stock, $0.0001 par value | 1,000 | $4.56 | $4,560.00 |
DisclosureSEC source: 0001567619-20-006202 · doc1.xml · nonDerivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 16:07 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $29.00 | $0.00 |
DisclosureSEC source: 0001567619-20-005799 · doc1.xml · derivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-04 F1 · derivative.exercise_date: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from March 4, 2020 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:29 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 14,050 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001209191-18-047549 · doc4.xml · derivative · entry 2 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,050 Underlying: Common Stock · 14,050 shares Expires 2028-08-14 F3 · derivative.exercise_date: 1/3rd of the total number of shares underlying this option shall vest on each of February 5, 2019, August 5, 2019 and February 5, 2020. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:29 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 21,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047549 · doc4.xml · nonDerivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,560 F1 · shares: Represents grant of the restricted stock units payable solely in common stock that vest as follows: 1/3rd of the total number of shares shall vest on each of February 5, 2019, August 5, 2019 and February 5, 2020. F2 · balance_after: Includes 602 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2018. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $16.95 | $0.00 |
DisclosureSEC source: 0001209191-18-016035 · doc4.xml · derivative · entry 2 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2028-02-27 F3 · derivative.exercise_date: The shares underlying this option shall vest as to 25% after one year following the grant date, and the remainder will vest in equal monthly installments over the following three years. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 19:20 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-016035 · doc4.xml · nonDerivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,858 F1 · shares: Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date. F2 · balance_after: Includes 1,572 shares and 1,286 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2017 and September 8, 2017, respectively. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:08 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-17-066697 · doc4.xml · derivative · entry 5 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,998 Underlying: Common Stock · 4,000 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:08 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-17-066697 · doc4.xml · derivative · entry 4 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,666 Underlying: Common Stock · 4,000 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:08 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Sale12/18/2017 | 8,000 | $20.00 | $160,000.00 |
DisclosureSEC source: 0001209191-17-066697 · doc4.xml · nonDerivative · entry 3 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 9, 2017. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:08 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 4,000 | $4.21 | $16,840.00 |
DisclosureSEC source: 0001209191-17-066697 · doc4.xml · nonDerivative · entry 2 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:08 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 4,000 | $1.16 | $4,640.00 |
DisclosureSEC source: 0001209191-17-066697 · doc4.xml · nonDerivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 16:27 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001209191-16-145801 · doc4.xml · derivative · entry 1 O'Neil Thomas P. · CIK 0001640645 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2026-10-11 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the vesting commencement date of August 10, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.